The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | BCL-2 frontline therapy in CLL
Michael Hallek, MD, University Hospital of Cologne, Cologne, Germany, explores why BCL-2 inhibition is a superior front-line treatment for patients with chronic lymphocytic leukemia (CLL) and highlights the benefit of combination therapy in CLL therapy, including agents such as venetoclax, obinutuzumab and ibrutinib for this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
